Sign In
Buy PLSE
$24.99
+0.710 (+2.92%)
At Close: Jun 03, 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA
PLSE Starts Research Work on nPulse Technology to Treat Thyroid Tumor
01:41pm, Wednesday, 10'th Dec 2025
Pulse Biosciences partners with MD Anderson to study its nPulse technology for treating benign and malignant thyroid tumors upon receiving FDA approval for a first-in-human trial.
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel nPulse™ technology using its proprietary Nanos
Critical Contrast: Pulse Biosciences (NASDAQ:PLSE) vs. ENDRA Life Sciences (NASDAQ:NDRA)
03:47am, Saturday, 22'nd Nov 2025
ENDRA Life Sciences (NASDAQ: NDRA - Get Free Report) and Pulse Biosciences (NASDAQ: PLSE - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast t
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 21'st Nov 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA
Pulse Biosciences, Inc. (PLSE) Q3 2025 Earnings Call Transcript
11:01pm, Wednesday, 05'th Nov 2025
Pulse Biosciences, Inc. ( PLSE ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Paul LaViolette - President, CEO & Co-Chairman of the Board Jon Skinner - Chief Financial Offic
Pulse Biosciences, Inc (PLSE) Reports Q3 Loss, Lags Revenue Estimates
07:16pm, Wednesday, 05'th Nov 2025
Pulse Biosciences, Inc (PLSE) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.16 per share a year ago.
Pulse Biosciences Reports Business Updates and Third Quarter 2025 Financial Results
04:05pm, Wednesday, 05'th Nov 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA
Pulse Biosciences Announces First Enrollment in the NANOCLAMP AF Study
07:00am, Friday, 24'th Oct 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA
Pulse Biosciences Schedules Third Quarter 2025 Business Updates and Financial Results Conference Call for November 5, 2025
04:05pm, Wednesday, 22'nd Oct 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Thursday, 16'th Oct 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA
Pulse Biosciences Unveils Promising First-in-Human Data for nPulse
09:15am, Monday, 13'th Oct 2025
PLSE unveils strong first-in-human data for its nPulse Cardiac Surgical System, showcasing safety, speed, and durable AF treatment potential.
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Wednesday, 17'th Sep 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA
